广西河池化工股份有限公司 会计师事务所选聘制度 第一章 总则 第一条 为了规范广西河池化工股份有限公司（以下简称"公司"）选聘（含续 聘、改聘）会计师事务所行为，提高财务信息质量，维护全体股东的合法权益和利 益，根据《中华人民共和国公司法》《中华人民共和国证券法》等相关法律法规、规 范性文件和《广西河池池化工股份有限公司章程》（以下简称《公司章程》）等有关 规定，结合公司实际情况，制定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规要求，聘 任会计师事务所对年度财务会计报告发表审计意见、出具审计报告的行为。公司聘 任会计师事务所从事除年度财务会计报告审计之外的其他法定审计业务的，可以比 照本制度执行。 （一）具有独立的法人资格，具备国家行业主管部门和中国证券监督管理委员 会（以下简称"中国证监会"）规定的开展证券期货相关业务所需的执业资格； （二）具有固定的工作场所、健全的组织机构和完善的内部管理和控制制度； （三）熟悉国家有关财务会计方面的法律、法规、规章和政策； （四）具有完成审计任务和确保审计质量的注册会计师； （五）认真执行有关财务审计的法律、法规、规章和政策规定，具有良好的社 ...

广西河池化工股份有限公司 董事会议事规则 二 O 二五年七月 第一章 总则 第一条 为健全和规范广西河池化工股份有限公司（以下简称 "公司"）董事会议事和决策程序，完善法人治理结构，提高董事会 工作效率和科学决策水平，保证公司经营管理工作的顺利开展，根据 《中华人民共和国公司法》（以下简称"《公司法》"）、证监会《上市 公司独立董事管理办法》（以下简称"管理办法"）、《上市公司治理准 则》、《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自 律监管指引第 1 号—主板上市公司规范运作》等法律法规的规定以及 《广西河池化工股份有限公司章程》（以下简称"《公司章程》"）之规 定，制定本议事规则。 第二条 董事会是公司经营管理的决策机构，维护公司和全体股 东的利益，在《公司章程》和股东会的授权范围内，负责公司发展战 略和重大经营活动的决策。 第三条 董事会依照法律、行政法规、《公司章程》及本规则的 相关规定行使职权，并对股东会负责。 第四条 董事会下设董事会办公室（证券部），处理董事会日常 事务。董事会秘书兼任董事会办公室负责人，负责保管董事会印章。 公司设董事会秘书，负责公司股东会和董事会会议的筹备、文件 ...

Group 1 - The A-share chemical pharmaceutical sector is experiencing a volatile correction, with companies such as Haichen Pharmaceutical and Yong'an Pharmaceutical both declining over 9% [1] - Other companies including Yipinhong, Hasanlian, Tonghua Jinma, Hanyu Pharmaceutical, and Hehua Co. have also seen declines of around 5% [1]

Core Insights - The Shanghai Composite Index rose by 0.43% on June 3, with 20 out of 28 sectors experiencing gains, particularly in the beauty care and textile sectors, which increased by 3.86% and 2.53% respectively [1] - The pharmaceutical and biotechnology sector saw a rise of 1.78%, with a net inflow of 9.17 billion yuan in capital [1] - Among the 475 stocks in the pharmaceutical sector, 416 stocks increased, with 14 hitting the daily limit up, while 54 stocks declined [1] Capital Flow Analysis - The pharmaceutical sector had 221 stocks with net capital inflows, with 6 stocks receiving over 100 million yuan in net inflows. Leading the inflow was Huahai Pharmaceutical with 266.1 million yuan, followed by Qianhong Pharmaceutical and Hehua Co., which received 201.5 million yuan and 168 million yuan respectively [1] - The outflow list included 6 stocks with net outflows exceeding 50 million yuan, with the highest outflows from Ruizhi Pharmaceutical, Hengrui Medicine, and Mindray Medical, which saw outflows of 237 million yuan, 110 million yuan, and 109 million yuan respectively [2] Pharmaceutical Sector Performance - The top gainers in the pharmaceutical sector included: - Huahai Pharmaceutical: +7.63%, turnover rate 7.71%, capital flow 266.1 million yuan - Qianhong Pharmaceutical: +10.05%, turnover rate 17.02%, capital flow 201.5 million yuan - Hehua Co.: +9.95%, turnover rate 18.47%, capital flow 167.7 million yuan [1] - The top decliners included: - Ruizhi Pharmaceutical: -13.15%, turnover rate 34.15%, capital flow -236.7 million yuan - Hengrui Medicine: -0.26%, turnover rate 0.68%, capital flow -109.7 million yuan - Mindray Medical: -3.02%, turnover rate 0.58%, capital flow -108.9 million yuan [2] ETF Insights - The Hang Seng Medical ETF, which tracks the Hang Seng Hong Kong-listed biotechnology index, experienced a 5-day increase of 3.59% with a net inflow of 9.86 million yuan [5]

Group 1 - The CRO concept index rose by 3.41%, ranking 6th among concept sectors, with 59 stocks increasing in value [1] - Leading stocks in the CRO sector included Lianhua Technology and Hehua Co., which hit the daily limit, while Tianyu Co. and Haitai Bio saw significant gains of 19.72% and 13.18% respectively [1] - The stocks with the largest declines included *ST Shuangcheng, Fosun Pharma, and Kailai Ying, which fell by 3.08%, 0.39%, and 0.24% respectively [1] Group 2 - The CRO sector experienced a net inflow of 0.45 billion yuan, with 25 stocks receiving net inflows, and 14 stocks attracting over 10 million yuan [2] - Hehua Co. led the net inflow with 1.68 billion yuan, followed by Lianhua Technology and Haoyuan Pharmaceutical with net inflows of 834.83 million yuan and 749.80 million yuan respectively [2] - The top stocks by net inflow ratio included Hehua Co. at 28.79%, Haoyuan Pharmaceutical at 12.05%, and Nearshore Protein at 11.73% [3] Group 3 - The trading volume and turnover rates for leading stocks in the CRO sector were notable, with Hehua Co. achieving a turnover rate of 18.47% and Lianhua Technology at 13.17% [3] - Other significant stocks included Yaosheng Technology and Sichuan Shuangma, which also showed positive performance with gains of 5.21% and 5.29% respectively [3] - Stocks like Tianyu Co. and Ruizhizhi Pharmaceutical had substantial trading activity, with Tianyu Co. rising by 19.72% and Ruizhizhi Pharmaceutical by 13.15% [5]

Core Viewpoint - The CRO (Contract Research Organization) sector has shown a positive performance with a 1.51% increase, ranking second among concept sectors, driven by significant gains in specific stocks like New Tian Di, which hit a 20% limit up [1][2]. Sector Performance - The CRO concept sector saw 42 stocks rise, with New Tian Di leading at a 20% increase, followed by Yang Guang Nuo He at 12.55%, Rui Zhi Yi Yao at 8.05%, and Hong Bo Yi Yao at 7.73% [1][2]. - Conversely, stocks like *ST Shuang Cheng, Si Chuan Shuang Ma, and Jin An Dan Bai experienced declines of 5.01%, 3.73%, and 3.19% respectively [1][2]. Capital Flow - The CRO sector experienced a net outflow of 507,500 yuan, with 29 stocks receiving net inflows. New Tian Di topped the list with a net inflow of 86,619,800 yuan, followed by Kang Long Hua Cheng with 58,064,600 yuan and Tai Ge Yi Yao with 49,707,000 yuan [2][3]. - The net inflow ratios for leading stocks included New Tian Di at 10.25%, Nuo Si Ge at 9.53%, and Kang Long Hua Cheng at 6.78% [3]. Stock Highlights - Key stocks in the CRO sector included: - New Tian Di: 20.02% increase, 57.74% turnover rate, net inflow of 86,619,800 yuan, net inflow ratio of 10.25% [3][4]. - Kang Long Hua Cheng: 2.38% increase, 2.58% turnover rate, net inflow of 58,064,600 yuan, net inflow ratio of 6.78% [3][4]. - Tai Ge Yi Yao: 5.64% increase, 4.82% turnover rate, net inflow of 49,707,000 yuan, net inflow ratio of 3.80% [3][4]. Declining Stocks - Notable declines included: - *ST Shuang Cheng: 5.01% decrease, with a significant net outflow of 1,391,440 yuan [5][6]. - Si Chuan Shuang Ma: 3.73% decrease, with a net outflow of 500,800 yuan [5][6]. - Jin An Dan Bai: 3.19% decrease, with a net outflow of 233,620 yuan [5][6].

证券代码：000953 证券简称：河化股份 公告编号：2025-018 广西河池化工股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 特别提示： 1.本次股东大会召开期间无增加、修改提案的情况，不存在否决提案的情况； 2.本次股东大会不存在变更以往股东大会已通过的决议的情况； 3.本次股东大会以现场投票及网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1.召开时间： （1）现场会议召开时间：2025 年 5 月 22 日 （星期四）14:30 1.股东出席的总体情况： 通过现场和网络投票的股东 285 人，代表股份 127,148,890 股，占公司有表 决权股份总数的 34.8120％。其中，通过现场投票的股东 2 人，代表股份 124,493,589 股，占公司有表决权股份总数的 34.0850％；通过网络投票的股东 283 人，代表股份 2,655,301 股，占公司有表决权股份总数的 0.7270％。 （2）网络投票时间： A、通过深圳证券交易所交易系统进行网络投票，时间为 202 ...

法律意见书 国浩律师（南宁）事务所受广西河池化工股份有限公司（以下简称"公 司"）的委托，指派李长嘉、黄赟律师（以下简称"本律师"）对公司2024 年年度股东大会（以下简称"本次股东大会"或"本次会议"）召开的全 过程进行见证并出具法律意见。 为出具法律意见，本律师审查了公司提供的有关会议文件、资料，公 司保证已向本律师提供了出具法律意见所必须的、真实的书面材料。 基于对上述文件、资料的审查和见证情况，本律师根据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司股东大会规则》《广 西河池化工股份有限公司章程》（以下简称"《公司章程》"）等有关规 定，按照律师行业公认的业务标准、道德规范和勤勉尽责的精神，对本次 股东大会发表法律意见。 法律意见书 法律意见书 国浩律师（南宁）事务所 2012 年第五次临时股东大会的 关于广西河池化工股份有限公司 法律意见书 2024 年年度股东大会的法律意见书 国浩律师（南宁）意字（2024）第 5069-3 号 2012 年第五次临时股东大会的 致：广西河池化工股份有限公司 本律师同意公司将本法律意见书与本次股东大会会议决议一同公告， 并依法对法律意见书承担法律责任 ...

这几只票暗盘资金正在偷偷流入，立即查看>> CRO概念板块短线拉升，河化股份（000953）涨停，金凯生科（301509）、睿智医药（300149）、诺 思格（301333）、昊帆生物（301393）、义翘神州（301047）等纷纷走高。 ...

Financial Performance - In Q1 2025, the net profit attributable to shareholders reached 1.362 million yuan, a significant increase of 217.42% compared to the same period last year, marking a turnaround from losses to profits [3] - The company has implemented cost reduction and efficiency enhancement measures, leading to improved overall profitability [3] Debt Management - The company repaid 60 million yuan of loans from controlling shareholders in Q1 2025 to reduce financial expenses [4] Risk Management - The company does not currently face delisting risk as per the Shenzhen Stock Exchange listing rules, despite concerns over small revenue [4] Business Development - The company plans to actively explore new business opportunities and expand market reach while ensuring compliance and risk control [4][6] - Focus will remain on core business areas, enhancing resource allocation, and increasing competitiveness through market-driven strategies [6] Shareholder Concerns - The restructuring of the controlling shareholder, Ningbo Yinyi Holdings, is ongoing, with a court-approved plan in October 2024 for a combined restructuring of 17 companies [6]